SCHEMBL731026

SCHEMBL731026

COC(=O)c1cc(-c2nc[nH]n2)cc(N2CCCC2)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 0.40
NPC1 O15118 4/20 0.40
RAB9A P51151 3/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
KMT2A Q03164 4/20 0.38
ALDH1A1 P00352 6/20 0.36
HPGD P15428 2/20 0.34
CYP11B2 P19099 1/20 0.34
WNT1 P04628 1/20 0.34
DYRK1A Q13627 1/20 0.34
MEN1 O00255 3/20 0.34
GAA P10253 1/20 0.34
HSD17B10 Q99714 1/20 0.34
IP6K1 Q92551 3/20 0.34
USP2 O75604 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
MAPT P10636 1/20 0.33
ALOX15 P16050 1/20 0.33
TSHR P16473 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL730994 0.86 ALDH1A1 (0.46) KDM4ENPC1RAB9ASMN1; SMN2KMT2A
SCHEMBL730949 0.79 KDM4E (0.53) KDM4ENPC1RAB9ASMN1; SMN2NPSR1
SCHEMBL742211 0.79 KDM4E (0.39) KDM4ENPC1RAB9ASMN1; SMN2NPSR1
SCHEMBL3510581 0.78 KDM4E (0.55) KDM4ENPC1RAB9ASMN1; SMN2NPSR1
SCHEMBL743462 0.76 NPC1 (0.38) KDM4ENPC1RAB9ASMN1; SMN2NPSR1
SCHEMBL730915 0.76 KDM4E (0.38) KDM4ENPC1RAB9ASMN1; SMN2NPSR1
SCHEMBL730950 0.74 ALDH1A1 (0.53) KDM4ENPC1RAB9ASMN1; SMN2NPSR1
SCHEMBL21817920 0.73 KDM4E (0.45) KDM4ENPC1RAB9ASMN1; SMN2NPSR1
SCHEMBL2276958 0.73 NOTUM (0.49) KDM4ENPC1RAB9ASMN1; SMN2NPSR1
SCHEMBL730837 0.73 KDM4E (0.50) KDM4ENPC1RAB9ASMN1; SMN2NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2120569-B1 SPIROCHROMANON DERIVATIVES MERCK SHARP & DOHME (US) 2013-08-14 EP disclosed
US-8138197-B2 Spirochromanon derivatives MSD K.K. (JP) 2012-03-20 US disclosed
EP-2120569-A2 SPIROCHROMANON DERIVATIVES Merck & Co., Inc. (US) 2009-11-25 EP disclosed
US-20090270436-A1 SPIROCHROMANON DERIVATIVES MERCK SHARP & DOHME LLC 2009-10-29 US disclosed
WO-2008088692-A2 SPIROCHROMANON DERIVATIVES MERCK & CO., INC. (US) 2008-07-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090270436-A1 SPIROCHROMANON DERIVATIVES AKR1C3, CBR3, AKR1C4 KDM4E 3445/4885NPC1 2438/4885RAB9A 2465/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.